Beyond The Abstract - Pathological Evidence Of Necrosis In Recurrent Renal Mass Following Treatment With Sunitinib
Jan 29th 2008Drug InformationUrology
UroToday.com - Sunitinib is a highly potent, selective inhibitor of certain protein tyrosine kinases, including VEGF-R types 1 to 3, PDGF-R- , and PDGF-R-ß. Preclinical data suggest that sunitinib has antitumor activity that may result from both inhibition of angiogenesis and direct antiproliferative effects on certain tumor cell types.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
